๐
Tecartus
brexucabtagene autoleucel
Linfoma, a cellule mantellari
โ
Autorizzato
Terapia avanzata
โ
Nessun allarme attivo
Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.
A cosa serve
Mantle cell lymphoma Tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Brutonโs tyrosine kinase (BTK) inhibitor. Acute lymphoblastic leukaemia Tecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
โ ๏ธ Sicurezza del paziente
No
Pagina ufficiale EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus